Microbiome Biotech Seres Sets Terms For $106M IPO
Venture capital-backed biotech company Seres Therapeutics Inc., which is developing microbiome therapies to replace beneficial bacteria in the gut, set terms for its initial public offering on Tuesday, looking to raise...To view the full article, register now.
Already a subscriber? Click here to view full article